AtriCure Inc
ATRC
ISIN US04963C2098 / Valor 2134051
AtriCure Inc
UMushroom community rating:
About company
AtriCure Inc. is a prominent medical device company specializing in the development and provision of advanced technologies aimed at the treatment of Atrial Fibrillation (Afib) and related cardiac conditions. The company has established itself as a trusted partner for electrophysiologists and cardiothoracic surgeons globally, offering a range of products designed to address complex cardiac cases. Among its notable innovations is the Isolator® Synergy™ Ablation System, distinguished as the first device of its kind to receive FDA approval for the treatment of persistent Afib. Additionally, AtriCure's AtriClip Left Atrial Appendage Exclusion System stands out as the most extensively utilized device worldwide for left atrial appendage management. The company also offers the Hybrid AF™ Therapy, a minimally invasive approach catering to patients with long-standing persistent Afib, and the cryoICE cryoSPHERE® probe, which is approved for the temporary ablation of peripheral nerves to alleviate pain during cardiac and thoracic surgeries. AtriCure is committed to advancing the field of cardiac care through continuous investment in innovation, clinical science, and educational initiatives aimed at enhancing patient outcomes globally.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.08.2024):
Revenue Growth
AtriCure Inc. reported worldwide revenue of $116.3 million for the second quarter of 2024, marking a 15.2% increase year over year. This growth was driven by strong adoption of their products globally, particularly in the U.S. pain management and international franchises.
U.S. Revenue
In the United States, AtriCure Inc. achieved revenue of $95.5 million for the second quarter of 2024, an increase of $10.6 million or 12.5% compared to the same period in 2023. Key product lines contributing to this growth included cryoSPHERE® probes for post-operative pain management and the AtriClip® Flex·V® device in appendage management.
International Revenue
International revenue for AtriCure Inc. in the second quarter of 2024 was $20.7 million, reflecting a significant increase of $4.7 million or 29.4% year over year. This growth was realized across all franchises and most major geographic regions.
Gross Profit and Margin
AtriCure Inc. reported a gross profit of $86.8 million for the second quarter of 2024, compared to $77.1 million for the same period in 2023. However, the gross margin decreased by 168 basis points to 74.7%, due to less favorable geographic and product mix, as well as increased product costs.
Financial Guidance
AtriCure Inc. has updated its full-year 2024 revenue guidance to approximately $456 million to $461 million, reflecting a growth of around 15% at the midpoint. The company also expects full-year 2024 Adjusted EBITDA to be in the range of $26 million to $29 million, representing a 34% to 49% increase over 2023.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1826 M
Market cap (USD)
117,077
Daily traded volume (Shares)
36.37 / 35.68
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
